AnaptysBio, Inc. (NASDAQ:ANAB) CEO Sells $64,260.00 in Stock

AnaptysBio, Inc. (NASDAQ:ANAB) CEO Daniel Faga sold 3,000 shares of the stock in a transaction dated Monday, March 25th. The shares were sold at an average price of $21.42, for a total value of $64,260.00. Following the completion of the transaction, the chief executive officer now directly owns 749,087 shares in the company, valued at approximately $16,045,443.54. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Daniel Faga also recently made the following trade(s):

• On Friday, March 22nd, Daniel Faga sold 145,940 shares of AnaptysBio stock. The shares were sold at an average price of $22.78, for a total value of $3,324,513.20.
• On Monday, January 8th, Daniel Faga sold 6,866 shares of AnaptysBio stock. The stock was sold at an average price of $21.81, for a total value of $149,747.46.

AnaptysBio Stock Performance

NASDAQ:ANAB opened at $21.38 on Thursday. The company has a market cap of $572.13 million, a PE ratio of -3.52 and a beta of -0.28. AnaptysBio, Inc. has a 52-week low of $13.36 and a 52-week high of $27.50. The stock has a 50-day simple moving average of $24.00 and a 200 day simple moving average of $20.21.

Analyst Ratings Changes

A number of equities research analysts have recently commented on ANAB shares. Wedbush raised AnaptysBio from a “neutral” rating to an “outperform” rating and raised their price target for the stock from $20.00 to $34.00 in a research report on Tuesday, March 12th. BTIG Research started coverage on AnaptysBio in a research report on Monday, February 26th. They set a “buy” rating and a $55.00 price target on the stock. Piper Sandler started coverage on AnaptysBio in a research report on Friday, February 16th. They set an “overweight” rating and a $80.00 price target on the stock. Finally, Stifel Nicolaus started coverage on AnaptysBio in a research report on Wednesday, February 21st. They set a “buy” rating and a $50.00 price target on the stock. One investment analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $45.00.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. Hudson Bay Capital Management LP grew its holdings in shares of AnaptysBio by 100.0% during the third quarter. Hudson Bay Capital Management LP now owns 100,000 shares of the biotechnology company’s stock worth $1,796,000 after buying an additional 50,000 shares in the last quarter. Jacobs Levy Equity Management Inc. increased its position in shares of AnaptysBio by 4.1% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 206,785 shares of the biotechnology company’s stock worth $3,714,000 after purchasing an additional 8,064 shares during the last quarter. Victory Capital Management Inc. acquired a new position in shares of AnaptysBio during the 3rd quarter worth approximately $785,000. Great Point Partners LLC increased its position in shares of AnaptysBio by 11.2% during the 2nd quarter. Great Point Partners LLC now owns 894,333 shares of the biotechnology company’s stock worth $18,191,000 after purchasing an additional 90,000 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of AnaptysBio by 134.4% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,896 shares of the biotechnology company’s stock worth $106,000 after purchasing an additional 3,381 shares during the last quarter.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.